Completed PHASE2 INTERVENTIONAL 1-arm NCT00420459

A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome

Aripiprazole in Fragile X Syndrome

Sponsor: Indiana University School of Medicine

Updated 8 times since 2017 Last updated: Mar 29, 2017 Started: Apr 30, 2007 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Fragile X Syndrome and is currently completed. Indiana University School of Medicine leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Jun 2017 [monthly]

Completed PHASE2

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indiana University School of Medicine

Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States